EvolutionaryScale's $142M seed shows investors are starting to bet on AI models that design biology, not just companies that engineer it by hand.
Synthetic biology has spent years being an engineering-intensive, capital-intensive field. A new wave of AI-native entrants is testing whether that capital intensity can be front-loaded into a model instead.
One seed round, bigger than most companies' entire funding history
EvolutionaryScale raised a $142M seed round, according to New Market Pitch's synthetic biology tracker, a round larger than the lifetime funding of many later-stage synthetic biology companies in the same dataset. The broader synthetic biology market has raised $9.1B across its top 60 ranked companies, per Seedtable, but most of that capital went to companies doing hands-on genetic engineering, precision fermentation, or cell programming, not AI models trained to design proteins computationally.
A related company, Pando, uses an AI-driven ultra-high-throughput screening platform that its founders say screens 1,000-fold more enzymes 75% faster and 80% cheaper than traditional methods, according to Y Combinator's portfolio listing, another example of the same underlying bet: that AI models can compress years of wet-lab iteration into a fraction of the time and cost.
Therapeutics-focused synthetic biology companies including Generate Biomedicines, ArsenalBio, Tessera, Senti Biosciences, and Obsidian Therapeutics have together raised about $3.2B, while food and materials-focused synthetic biology, Impossible Foods, Perfect Day, Solugen, Pivot Bio, and Motif FoodWorks, have raised roughly $4.5B combined, showing therapeutics is catching up fast to a category that used to be dominated by food and materials.
A different capital efficiency story entirely
Traditional synthetic biology platforms need lab infrastructure, wet-lab scientists, and iterative testing cycles that take months per design. An AI-native approach front-loads that cost into training a model once, then running inference cheaply and quickly for every subsequent design. If that bet is right, it changes the unit economics of the entire category, and explains why a seed-stage AI biology company can raise more than an established synthetic biology platform with years of lab work behind it.
It's also a cautionary tale worth remembering: Amyris and Motif FoodWorks together absorbed about $1.5B in synthetic biology funding before shutting down, proof that capital alone doesn't solve the field's underlying scale-up risk, whether that capital comes from a lab-heavy platform or an AI-native one.
Whether the model-first bet actually ships products faster
Watch whether EvolutionaryScale and similar AI-native biology companies can convert their computational speed advantage into actual shipped products faster than traditional wet-lab platforms, since the real test isn't how fast a model can design a candidate, it's how fast that candidate survives real-world validation, manufacturing, and regulatory review, the same bottleneck that's already slowing down cell and gene therapy more broadly.
